MSMari Jeeva Sankar

Mari Jeeva Sankar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mari Jeeva Sankar has a total of 457 co-authors. Here are the top co-authors by number of shared publications:

  • Ramesh Agarwal

    Division of Neonatology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India

    27 shared publications
  • Ramesh Agarwal

    Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, Delhi, India

    22 shared publications
  • Anu Thukral

    Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, Delhi, India

    17 shared publications
  • Vinod K. Paul

    Department of Pediatrics, All India Institute of Medical Sciences (AIIMS), New Delhi, India

    12 shared publications
  • Anu Thukral

    Division of Neonatology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India

    11 shared publications
  • Vivek Kumar

    Division of Neonatology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India

    11 shared publications

Latest Publications

  • Neonatal sepsis

    by Angela Dramowski, Adrie Bekker, Julia Bielicki, Felicity Fitzgerald, Julia Johnson, Lizel Lloyd, Flavia Namiiro, Mari Jeeva Sankar, Phoebe C. M. Williams, Sithembiso C. Velaphi

  • Predictors of Failure of Conventional Dose Caffeine Therapy in Neonates Below 32 Weeks' Gestation: An Ambispective Cohort Study

    by Purna Chandra, Satya Prakash, Vivek Kumar, Akash Sharma, Ankit Verma, Anu Thukral, Thirumurthy Velpandian, M Jeeva Sankar, Ramesh Agarwal

  • Open Access

    Discovery and Validation of Serum Metabolic Signature of Neonatal Sepsis

    by Riya Ahmed, Suraj Thottathil, Nidhi Yadav, Anil Behera, Adyasha Sarangi, Vrinda Satheesan Nair, Pradeep Debata, Rajni Gaind, Gp Kaushal, Renu Gur, et al.

    A more accurate diagnostic biosignature is crucial for neonatal sepsis. In this report, we identified a serum metabolite signature for diagnosing neonatal sepsis cases using mass spectrometry-based profiling of serum samples from two discovery cohorts (set-I/-II: n=71/269) of sepsis patients (culture positive/negative: CP/CN) and controls (no-sepsis: NS or healthy controls: HC). This signature was validated in both cross-sectional (n=60) and follow-up cohorts (n=100). The six-metabolite signature, which includes 1,5-anhydro-D-sorbitol, lactic acid, malic acid, myo-inositol, phenylalanine, and lysine, can distinguish CP and CN sepsis cases from HC. The deregulated serum metabolites returned to HC levels in neonates after completing antibiotic treatment. Additionally, a metabolic signature of PE (20:4(5Z,8Z,11Z,14Z)/0:0), 12-amino-dodecanoic acid, and 1,5-anhydro-D-sorbitol identified from a validation set-II (n=100) using LC-MS could differentiate CP and CN groups from NS groups. Translating this serum metabolite signature into a simple, deployable blood test for neonatal sepsis could enable faster and more accurate decision-making.

  • Trends in neonatal mortality and morbidity at a tertiary centre over four decades: a cohort study

    by Satya Prakash, Manju Saksena, Tanushree Sahoo, Lumchio Levis Murry, Alphy K Vijayan, Suman Dabas, Heena Dabas, Akash Sharma, Anurag Bajpai, Ankit Verma, et al.

    Objectives: Long-term, hospital-based data on neonatal outcomes from low- and middle-income countries remain scarce, hindering identification of scalable interventions that improve survival in resource-constrained settings. This study aimed to describe secular trends in neonatal mortality and morbidities over four decades in an Indian neonatal unit. Design: Retrospective cohort study. Setting: Single tertiary-level academic public hospital (New Delhi, India). Participants: All inborn neonates born between 1983 and 2023 (n=80 208). Main outcome measures: Neonatal mortality rates (NMR), significant morbidities and sepsis analysed across eight epochs of 4–6 years each. Results: NMR declined considerably in the first three epochs (30.7 to 18.2 per 1000 live births in epoch III) despite an increase in preterm and multiple births but remained stagnant thereafter (17.6 in epoch 8). The survival of very low birthweight neonates increased from 52% (102/197) to 79% (503/639). The incidence of severe perinatal asphyxia (2.4% to 1.3%), severe intraventricular haemorrhage (4.7% to 1.1%) and respiratory distress syndrome (33.1% to 12.5%) decreased, while that of major malformations (2.1% to 3.1%) increased. The incidence of culture-positive sepsis, initially static at around 1.3–2% of live births, declined in the last two epochs (0.7%), with a shift in pathogen profile towards Gram-positive predominance. Conclusion: Neonatal survival improved substantially despite progressively higher sickness levels, stemming largely from the improved survival of very low birthweight neonates. We noted significant temporal changes in the morbidity profile and the pathogen profile. Sustained improvements in infection control, antenatal care and intensive support for smaller neonates appear to have contributed to these gains.


  • Open Access

    Contribution of nosocomial transmission to Klebsiella pneumoniae neonatal sepsis in Africa and South Asia: An observational study of infection clusters inferred from pathogen genomics and temporal data

    by Erkison Ewomazino Odih, Jabir A. Abdulahi, Anne V. Amulele, Matthew Bates, Eva Heinz, Weiming Hu, Kajal Jain, Rindidzani Magobo, Courtney P. Olwagen, John M. Tembo, et al.

    Background: Klebsiella pneumoniae is the leading cause of sepsis among neonates in low- and middle-income countries (LMICs) in Africa and Asia, contributing substantially to the overall burden of antimicrobial-resistant infections and mortality among neonates globally. Pathogen sequencing has been used to investigate case clusters and confirm nosocomial transmission in a small number of neonatal units. Here we utilise pathogen sequence data to estimate the fraction of K. pneumoniae neonatal sepsis attributable to nosocomial transmission in African and South Asian countries. Methods and findings: We estimated the proportion of invasive K. pneumoniae disease involved in nosocomial transmission clusters in a given neonatal unit, using single-linkage clustering based on pairwise temporal and genetic distances estimated from bacterial whole-genome sequences aggregated from 10 contributing studies. Analysing 1,523 K. pneumoniae isolates from 27 units in 13 countries in Africa and South Asia between 2013 and 2023, we inferred 156 nosocomial transmission clusters, ranging from 2 to 188 neonates each (83 of the clusters comprised ≥3 cases). Overall, we estimated that 1,035 neonatal infections (68.0%) were part of nosocomial transmission clusters. Excluding the first infection in each cluster as a potential index case, we estimate at least 879 (57.7%) infections were acquired via nosocomial transmission. Sensitivity analyses showed that results were robust to the choice of genetic distance estimation methods and thresholds used to define clusters, and cluster estimates were stable over temporal distance thresholds ranging from 2 to 8 weeks. Isolates were mostly extended-spectrum beta-lactamase (ESBL) producers (90.9%) and included 172 multi-locus sequence types (STs). Fourteen STs, including several globally recognised multidrug-resistant lineages, were associated with transmission clusters at multiple units, and these were collectively responsible for two-thirds of all infections. Carriage of carbapenemase genes (adjusted odds ratio, aOR = 2.08 [95% confidence interval, CI: 1.04, 4.14]; p = 0.04) and ESBL genes (aOR = 2.48 [95% CI: 1.26, 4.90]; p = 0.006) were significantly positively associated with transmission in a logistic regression model with site as a covariate. Limitations of this study include the lack of sufficient clinical data to allow high-resolution investigation of transmission dynamics and lack of facility-level data to investigate contributors to the observed differences in transmission burden across sites. Conclusions: Nosocomial transmission contributes to a substantial proportion of K. pneumoniae sepsis in neonatal care units in Africa and South Asia. Reducing transmission within these settings through improved infection prevention and control and other measures could substantially reduce the neonatal sepsis burden. A high burden of transmission clusters is associated with the same drug-resistant lineages that are recognised as high-risk clones associated with hospital outbreaks in high-income countries, indicating global connectivity of the antimicrobial-resistant pathogen population.


  • Open Access

    A machine learning model for prediction of early-onset neonatal sepsis in low-income and middle-income countries: development and validation study

    by Deepika Kainth, Ayushi Gupta, Pradeep Singh, Satya Prakash, Anu Thukral, Ashok Deorari, Mudit Kapoor, Ramesh Agarwal, Tavpritesh Sethi, M Jeeva Sankar

    Objective: Early-onset sepsis (EOS), which occurs within the first 72 hours of life, can often be fatal for neonates. Machine learning (ML) models demonstrate promise for timely diagnosis. However, current ML models primarily rely on data from high-income countries, which reduces their applicability to low-income and middle-income countries (LMICs) that have a higher burden and different disease profiles. We developed an ML model for the timely prediction of culture-proven EOS in LMICs. Methods: We conducted a secondary analysis of the Delhi Neonatal Infection Study (2011–2014) carried out in three level-3 neonatal units in India. Data from inborn neonates suspected of having EOS were extracted, and cases of culture-negative sepsis were excluded. By implementing a dynamic 80:20 (train:test) data split, two feature selection methods were employed—Boruta and Lasso—across 64 variables, and five ML techniques were applied. The aim was to achieve 90% sensitivity to identify the optimal model based on performance metrics. The developed model was integrated into a web application and validated in an external cohort of neonates born between 2015 and 2021. Results: Of 2924 neonates, 548 (18.7%) had culture-proven sepsis. The mean gestation and birth weight were 35.3 (±3.8) weeks and 2112 (±754) g, respectively. The Boruta and random forest classifier yielded the best model, which included 28 perinatal–neonatal variables. The sensitivity and specificity of the model were 90.3% and 40.6%, respectively. In external validation (n=147; 26 culture-proven sepsis cases), the model’s sensitivity, specificity, positive predictive value and negative predictive value were 92.3%, 37.2%, 24.0% and 95.7%, respectively. The sensitivity was 100% in asymptomatic neonates with only perinatal risk factors for EOS. The use of the model could have reduced antibiotic usage from 74.8% to 55.7% (risk difference: −19.1%; 95% CI −8.3 to −29.7). Conclusions: The ML model demonstrated high sensitivity and acceptable specificity in predicting EOS. This prediction model has the potential to assist in the timely and reliable identification of culture-positive sepsis and may serve as a bedside decision support tool in LMICs.


  • Visual assessment of bilirubin and transcutaneous bilirubinometry in detecting rebound hyperbilirubinemia requiring phototherapy re-initiation in neonates: a prospective diagnostic accuracy study

    by Priyanka Singh, Satya Prakash, Ankit Verma, Anu Thukral, Ramesh Agarwal, M Jeeva Sankar

    To evaluate the diagnostic performance of and the potential reduction in blood sampling by (a) visual assessment (VA) for jaundice and (b) transcutaneous bilirubinometry (TcB) at 12–24 h after stopping phototherapy in detecting rebound hyperbilirubinemia requiring re-initiation of phototherapy in neonates born at ≥ 35 weeks’ gestation. This prospective observational study was conducted at a tertiary neonatal unit in India. Eligible neonates underwent VA using Modified Kramer’s method by a neonatal fellow with > 3 years of pediatrics training, TcB using Dräger JM-105™, and total serum bilirubin (TSB) by point-of-care spectrophotometry (One Beam; Ginevri, Italy) at either 12 h (neonates with hemolytic jaundice) or 24 h (neonates with non-hemolytic jaundice) after phototherapy cessation. Outcomes included sensitivity, specificity, likelihood ratios, and reduction in TSB sampling. Among 160 enrolled neonates (gestation: 36 ± 3 weeks; birthweight: 2743 ± 483 g; 35 [21.9%] with hemolytic jaundice), rebound hyperbilirubinemia occurred in 8 (5%). Sensitivity was 100% for both VA and TcB, with VA demonstrating higher specificity (88.2% vs. 71.7%). Positive predictive values were low (VA: 30.8%; TcB: 15.7%), while negative predictive values were 100% for both. Positive likelihood ratios for VA and TcB were 8.4 and 3.5, respectively. VA and TcB could have reduced TSB sampling in 134 (83.8%; 95%CI 77.0–88.7) and 109 (68.1%; 95%CI 60.4–70.9) neonates, respectively. Conclusions: Given their excellent sensitivity and negative predictive values, VA and TcB can enable ruling out rebound hyperbilirubinemia after stopping phototherapy. Using them as primary screening tools can significantly reduce the need for blood sampling to detect rebound hyperbilirubinemia. What is Known: • Rebound hyperbilirubinemia requiring re-initiation of phototherapy occurs in a subset of neonates with pathological hyperbilirubinemia. • While visual assessment (VA) and transcutaneous bilirubinometry (TcB) are non-invasive methods for monitoring jaundice, their role in identifying rebound hyperbilirubinemia remains unclear. What is New: • This study shows excellent sensitivity and negative predictive values of VA and TcB for detecting rebound hyperbilirubinemia. • The results suggest the potential of these two non-invasive methods to decrease blood sampling for serum bilirubin levels, making them valuable tools particularly in resource-constrained settings.


  • Top Cited Papers
    Open Access

    Distribution of capsule and O types in Klebsiella pneumoniae causing neonatal sepsis in Africa and South Asia: A meta-analysis of genome-predicted serotype prevalence to inform potential vaccine coverage

    by Thomas D. Stanton, Shaun P. Keegan, Jabir A. Abdulahi, Anne V. Amulele, Matthew Bates, Eva Heinz, Yogesh Hooda, Weiming Hu, Kajal Jain, Samiah Kanwar, et al.

    Background: Klebsiella pneumoniae causes ~20% of sepsis in neonates, with ~40% crude mortality. A vaccine administered to pregnant women, protecting against ≥70% of K. pneumoniae infections, could avert ~400,000 cases and ~80,000 deaths annually, mostly in Africa and South Asia. Vaccine formulations targeting the capsular polysaccharide (K) or lipopolysaccharide (O) antigens are in development. Global K. pneumoniae populations display extensive K and O diversity, necessitating a polyvalent vaccine targeted to the serotypes associated with neonatal disease in relevant geographical regions. We investigated the prevalence of K and O types associated with neonatal sepsis in Africa and South Asia to inform maternal vaccine design. Methods and findings: We analysed 1,930 K. pneumoniae neonate blood isolates from 13 surveillance studies across 35 sites in 13 countries. We used pathogen whole-genome sequencing to predict K and O serotypes and adjust for local transmission clusters, and Bayesian hierarchical meta-analysis to estimate K and O prevalence overall and per region, treating site as a random effect. Eighty-seven K loci were identified. KL2, KL102, KL25, KL15, and KL62 accounted for 49% of isolates. We estimate that 20 K loci, combining the eight most prevalent per region, could cover 72.9% of all infections (95% credible interval: [69.4%, 76.5%]) and ≥70% in each of Eastern, Western, and Southern Africa and South Asia. Preliminary findings from three sites suggested sufficient temporal stability of K loci to maintain 20-valent K vaccine coverage over 5–10 years, but more longitudinal data are needed to support this prediction. O types were far less diverse ( n = 14 types). We estimate the top-5 (O1⍺β,2⍺, O1⍺β,2β, O2⍺, O2β, and O4) would cover 86.2% [82.6, 89.9%] of total infections (76%–92% per region), while the top-10 would cover ~99% of infections in all four regions. The main limitations of our study are the reliance on genome sequences to predict K and O serotypes (as serological typing is not available) and a lack of longitudinal data to explore stability of antigen prevalence over time. Conclusions: Neonatal sepsis is associated with diverse K and O types, with substantial geographic and temporal variation even after adjusting for localised transmission clusters. Despite this, a single 20-valent K vaccine could theoretically cover ≥70% of infections in all target regions. Locally-targeted vaccines could achieve higher coverage with lower valency, but are less feasible. In principle, very high coverage could be achieved with lower valency O-based vaccines, however, the protective efficacy against disease of antibodies targeting the O antigen remains uncertain. Further research is needed on cross-reactivity, antigen exposure, and stability of antigens over time, to better inform vaccine development.


  • Open Access

    Effect of different Iron-Folic acid (IFA) formulations, doses, and frequencies on pregnancy and neonatal outcomes compared to multiple micronutrients (MMN) among pregnant women: a systematic review and meta-analysis

    by Manyata Srivastava, Annu Gulia, Ashish Datt Upadhyay, Kamalesh Kumar Patel, Mari Jeeva Sankar, Anju Sinha, Pradeep Kumar

    Iron-Folic Acid (IFA) supplementation during pregnancy is widely recommended to prevent maternal anemia and improve birth outcomes. However, the optimal fo


  • Open Access

    Neutropenia, Thrombocytopenia and Cholestasis in Infants with Rhesus Hemolytic Disease

    by Satya Prakash, Ankit Verma, Tushar Sehgal, Mukul Aggarwal, M. Jeeva Sankar, Ramesh Agarwal, Anu Thukral